Department of Neurology, Columbia University, New York, New York, USA.
Mov Disord. 2010;25 Suppl 1:S110-6. doi: 10.1002/mds.22787.
Over the last decade, the importance of cognitive impairment and dementia in Parkinson's disease (PDD) has been increasingly recognized. Investigators have proposed criteria for PD dementia, and mild cognitive impairment. Risk profiles associated with the development of dementia based on demographic, neurological, neuropsychological, imaging, and genetic investigations have been delineated. The FDA has approved a treatment for PDD, and efforts now are directed toward intervention at earlier stages of cognitive impairment.
在过去的十年中，帕金森病（PDD）中认知障碍和痴呆的重要性日益受到重视。研究人员已经提出了 PD 痴呆和轻度认知障碍的标准。基于人口统计学、神经学、神经心理学、影像学和遗传学研究，已经确定了与痴呆发展相关的风险特征。FDA 已经批准了一种治疗 PDD 的药物，现在的努力方向是在认知障碍的早期阶段进行干预。
